Aptorum Group Limited (NASDAQ: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum's current drug pipeline includes indications in orphan diseases, infectious diseases, and metabolic diseases. In 2021, the company plans to bring two candidates to clinical trials. Aptorum’s Smart-ACT™ platform is designed to bring an average of three drug candidates for orphan diseases to clinical trials every 12-18 months. The company is now preparing to launch a dietary supplement for women undergoing menopause and experiencing related symptoms, including osteoporosis. Targeting a global woman’s health supplement market that is expected to reach $17 billion in 2025, Aptorum is expected to generate near-term revenue with significant long-term growth potential.
Project Portfolio Highlights
Aptorum Group: Robust Development Pipeline Targeting Multiple Indications
Aptorum’s four core assets (RPIDD, SACT-1, ALS-4, NLS-2) target indications with a combined market value of more than $250 billion. The company is building a diverse portfolio of over 12 projects primarily in therapeutics and diagnostics across a wide range of unmet disease areas. Aptorum translates early-stage discovery into proof-of-concept clinical stages and transforms clinical outcomes through licensing, co-development, and commercialization. The company’s proprietary Smart-ACT™ platform combines a computational approach and wet lab validation to screen over 2,600 approved small molecule drugs. This process allows Aptorum to identify candidates that can be repurposed for selected orphan or unmet diseases. This platform’s first proof-of-concept asset is SACT-1 for Neuroblastoma, a cancer mostly affecting children that develops from immature nerve cells. SACT-1 was also recently used to identify at least three small molecule drugs targeting COVID-19, which Aptorum is investigating in collaboration with Covar Pharmaceuticals and the University of Hong Kong’s Microbiology Department.
Aptorum Group: Three-Pillar Drug Development Strategy with Near-Term Revenue
Four core assets showing significant progress:
- Rapid Pathogen Identification and Detection Diagnostics (“RPIDD”) technology, a rapid, accurate, cost-effective and untargeted method to identify and detect existing or emerging unknown pathogens through liquid biopsy. Such unknown pathogens include DNA/RNA-based viruses such as coronavirus, antibiotic-resistant bacteria, fungi, etc.
- SACT-1, a repurposed drug candidate for treating neuroblastoma discovered through its Smart-ACTTM drug discovery Platform.
- ALS-4, a small drug molecule candidate for the treatment of infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
- NLS-2, a dietary supplement for the relief of menopausal symptoms.
Two clinical candidates targeted to reach clinical phases in 2021, one of the candidates, ALS-4, has obtained regulatory approval of the Phase 1 clinical trials:
- SACT-1 for neuroblastoma Phase 1b/2a trial (global c. $2.6 billion market)
- ALS-4 for Staphylococcus aureus (incl. MRSA) infections Phase 1 trial (global c.$3.0 billion market)
- Near-term commercialization of dietary supplement for woman’s menopausal health (global c. $17 billion supplement market) expected to begin generating revenue in first half of 2021
- Three additional SACT programs underway, including investigation of at least three repurposed drug candidates for coronavirus (COVID-19) in collaboration with Covar Pharmaceuticals and The University of Hong Kong
- 12+ therapeutic candidates under development in areas including infectious diseases, gastrointestinal microbiome, and drug repurposing for orphan diseases; representing a combined over $8 billion+ global market opportunity
- Multiple analysts’ buy recommendations with price targets as high as $35
- Over 50+ staff, clinical advisors and consultants with vast experience in drug development and clinical trials, including US FDA, EMA, and NMPA purposes.